FOLH1 and prostate carcinoma: This review aims to summarize the clinical data of 177Lu-PSMA and 225Ac-PSMA RNT in patients with mCRPC and to provide future perspectives on RNT in prostate cancer patients, such as applying these therapies in earlier stages or exploration of other potential radionuclides.